# An Open-Label, Two-Part Study Designed to Assess the Absolute Bioavailability and Mass Balance of Aramchol

> **NCT05874336** · PHASE1 · COMPLETED · sponsor: **Galmed Pharmaceuticals Ltd** · enrollment: 6 (actual)

## Conditions studied

- NASH

## Interventions

- **DRUG:** Aramchol

## Key facts

- **NCT ID:** NCT05874336
- **Lead sponsor:** Galmed Pharmaceuticals Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-06-17
- **Primary completion:** 2020-08-11
- **Final completion:** 2020-08-11
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2023-05-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05874336

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05874336, "An Open-Label, Two-Part Study Designed to Assess the Absolute Bioavailability and Mass Balance of Aramchol". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT05874336. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*